Autophagy inhibition improves chemosensitivity in BRAF(V600E) brain tumors

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Autophagy inhibition is a promising cancer therapy, but its efficacy varies by tumor type.
• The BRAF V600E mutation is prevalent in pediatric central nervous system (CNS) tumors and influences cellular autophagy.
• Understanding the role of autophagy in BRAF-mutated tumors is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the role of autophagy in pediatric CNS tumors with BRAF V600E mutations.
• To evaluate the efficacy of autophagy inhibition as a therapeutic strategy in these tumors.
• To explore combination therapies involving autophagy inhibitors and standard treatments.

Main Methods:

• Assessed autophagy rates in BRAF V600E-mutated and wild-type CNS tumor cells.
• Tested sensitivity to pharmacologic and genetic autophagy inhibition.
• Evaluated synergistic effects of chloroquine with vemurafenib and chemotherapeutics in vitro and in ex vivo cultures.
• Documented a pediatric case study of combination therapy.

Main Results:

• BRAF V600E-mutated CNS tumor cells exhibited high induced autophagy rates.
• These cells were sensitive to both pharmacologic and genetic autophagy inhibition.
• Chloroquine demonstrated synergy with vemurafenib and standard chemotherapeutics.
• Chloroquine improved vemurafenib sensitivity in resistant ex vivo cultures and a patient case.

Conclusions:

• Pediatric CNS tumors with BRAF V600E mutations are dependent on autophagy.
• Autophagy inhibition, particularly with chloroquine, is a viable therapeutic strategy for these tumors.
• Combination therapy with autophagy inhibitors offers a promising approach to overcome resistance and improve clinical outcomes.